ACRS
Aclaris Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.48 / 10
Outperform
Fund-flow analysis shows a strong 7.59/10 score, highlighting robust liquidity momentum—particularly positive Extra-large inflows—despite negative trends in other buckets. Analyst sentiment is overwhelmingly bullish (100% Strong Buy from HC Wainwright). Together, these elements suggest underlying institutional confidence that may help stabilize the stock amid technical and fundamental headwinds.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionHC Wainwright & Co.
Times predicted5
Historical Win Rate60.0%
Is money flowing into or out of ACRS?
- ACRS holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.48/10 (Outperform).
